istock-183060916

oonal / iStockphoto.com

19 February 2018Americas

Roche to make $1.9bn acquisition

Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Eli Lilly to buy immuno-oncology firm in $1.6bn deal

11 May 2018 Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.

Roche to pay $2.4bn for remainder of Foundation Medicine

20 June 2018 Switzerland-based Roche has agreed to pay $2.4 billion to acquire the remainder of Foundation Medicine, a molecular and genomic analysis company headquartered in Cambridge, Massachusetts.

Roche to make $4.3bn gene therapy acquisition

25 February 2019 Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More on this story

Eli Lilly to buy immuno-oncology firm in $1.6bn deal

11 May 2018 Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.

Roche to pay $2.4bn for remainder of Foundation Medicine

20 June 2018 Switzerland-based Roche has agreed to pay $2.4 billion to acquire the remainder of Foundation Medicine, a molecular and genomic analysis company headquartered in Cambridge, Massachusetts.

Roche to make $4.3bn gene therapy acquisition

25 February 2019 Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More on this story

Eli Lilly to buy immuno-oncology firm in $1.6bn deal

11 May 2018 Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.

Roche to pay $2.4bn for remainder of Foundation Medicine

20 June 2018 Switzerland-based Roche has agreed to pay $2.4 billion to acquire the remainder of Foundation Medicine, a molecular and genomic analysis company headquartered in Cambridge, Massachusetts.

Roche to make $4.3bn gene therapy acquisition

25 February 2019 Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York